These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26080810)

  • 21. Sericin nanomicelles with enhanced cellular uptake and pH-triggered release of doxorubicin reverse cancer drug resistance.
    Guo W; Deng L; Yu J; Chen Z; Woo Y; Liu H; Li T; Lin T; Chen H; Zhao M; Zhang L; Li G; Hu Y
    Drug Deliv; 2018 Nov; 25(1):1103-1116. PubMed ID: 29742945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro.
    Leiva MC; Ortiz R; Contreras-Cáceres R; Perazzoli G; Mayevych I; López-Romero JM; Sarabia F; Baeyens JM; Melguizo C; Prados J
    Sci Rep; 2017 Oct; 7(1):13506. PubMed ID: 29044153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanism of inhibition of P-glycoprotein mediated efflux by Pluronic P123/F127 block copolymers: relationship between copolymer concentration and inhibitory activity.
    Wei Z; Yuan S; Hao J; Fang X
    Eur J Pharm Biopharm; 2013 Feb; 83(2):266-74. PubMed ID: 23089310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversing the direction of drug transport mediated by the human multidrug transporter P-glycoprotein.
    Sajid A; Lusvarghi S; Murakami M; Chufan EE; Abel B; Gottesman MM; Durell SR; Ambudkar SV
    Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29609-29617. PubMed ID: 33168729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymeric Drug-Delivery Systems: Role in P-gp Efflux System Inhibition.
    Gupta P; Garg T; Tanmay M; Arora S
    Crit Rev Ther Drug Carrier Syst; 2015; 32(3):247-75. PubMed ID: 26080810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging advances in P-glycoprotein inhibitory nanomaterials for drug delivery.
    Kou L; Sun R; Bhutia YD; Yao Q; Chen R
    Expert Opin Drug Deliv; 2018 Sep; 15(9):869-879. PubMed ID: 30169976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.
    Binkhathlan Z; Lavasanifar A
    Curr Cancer Drug Targets; 2013 Mar; 13(3):326-46. PubMed ID: 23369096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-ionic Surfactants as a P-Glycoprotein(P-gp) Efflux Inhibitor for Optimal Drug Delivery-A Concise Outlook.
    Rathod S; Desai H; Patil R; Sarolia J
    AAPS PharmSciTech; 2022 Jan; 23(1):55. PubMed ID: 35043278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment.
    Waghray D; Zhang Q
    J Med Chem; 2018 Jun; 61(12):5108-5121. PubMed ID: 29251920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent inhibitors of transporter-dependent multidrug resistance (MDR).
    Teodori E; Dei S; Martelli C; Scapecchi S
    Curr Top Med Chem; 2010; 10(17):1715-31. PubMed ID: 20645921
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.